Non-ST segment elevation acute coronary syndrome

Active Ingredient: Clopidogrel

Indication for Clopidogrel

Population group: only adults (18 years old or older)

Therapeutic intent: Preventive action

Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).

For this indication, competent medicine agencies globally authorize below treatments:

300 mg or 600 mg loading dose and thereafter 75 mg once daily

For:

Dosage regimens

Regimen A

Oral, 300 milligrams clopidogrel, one dose, over the duration of 1 day. Afterwards, oral, 75 milligrams clopidogrel, once daily.

Regimen B

Oral, 600 milligrams clopidogrel, one dose, over the duration of 1 day. Afterwards, oral, 75 milligrams clopidogrel, once daily.

Detailed description

Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg or 600 mg loading dose. A 600 mg loading dose may be considered in patients <75 years of age when percutaneous coronary intervention is intended. Clopidogrel treatment should be continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). Since higher doses of ASA were associated with higher bleeding risk it is recommended that the dose of ASA should not be higher than 100 mg. The optimal duration of treatment has not been formally established. Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months.

If a dose is missed:

Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time.
For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose.

Active ingredient

Clopidogrel
Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation. Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. Read more about Clopidogrel

Related medicines

Summary of Product Characteristics (SPC) 2024: ISCOVER Film-coated tablet

Structured Product Labeling (SPL/PLR) 2020: PLAVIX Film-coated tablet

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.